Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston gets US nod for Liberte stent, firm pits DES vs bypass

This article was originally published in Clinica

Executive Summary

The US FDA has given Boston Scientific the all-clear to sell its new bare metal coronary stent, Liberte, which will also serve as the platform for the firm's next-generation paclitaxel-eluting stent, Taxus Liberte. The company has also begun what it calls a groundbreaking trial to compare drug-eluting stents (DESs) with heart bypass surgery in patients with the severest form of coronary artery disease.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT054856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel